CTOs on the Move

Alsius Corporation

www.alsius.com

 
Alsius Corporation (Alsius) is a commercial-stage medical device company that develops, manufactures and sells products to precisely control patient temperature in hospital critical care settings. The Company operates through its wholly owned subsidiary,
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.alsius.com
  • 15770 Laguna Canyon Rd Ste 150
    Irvine, CA USA 92618
  • Phone: 949.453.0150

Executives

Name Title Contact Details

Similar Companies

Pervasis Therapeutics Inc

Pervasis Therapeutics Inc is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayhill Therapeutics

Bayhill Therapeutics is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precigen

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

The Public Health Company

PHC empowers organizations to proactively manage infectious disease risk through global disease forecasting, risk analysis, and practical guidance. PHC was founded by Dr. Charity Dean, and employs a world-class team of public health professionals, tech...

Appili Therapeutics

Appili Therapeutics is building a team of drug development professionals dedicated to advancing novel therapeutics in the area of infectious disease. Formed in mid 2015 & backed by Bloom Burton & Co, Appili has commenced development on two anti-infective programs, while continuing its search for additional high quality anti-infective assets at all stages of development.